Weight gain, obesity, and psychotropic prescribing

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Nihalani, Nikhil ^a   Schwartz, Thomas L ^b   Siddiqui, Umar A ^b   Megna, James L ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863685787     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/893629     Document Type: Review

References (109)

1. Allison D. B., Mentore J. L., Heo M., Chandler L. P., Cappelleri J. C., Infante M. C., Weiden P. J., Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999 156 11 1686 1696 2-s2.0-0032751075 (Pubitemid 29517559)
2. Masand P. S., Weight gain associated with psychotropic drugs. Expert Opinion on Pharmacotherapy 2000 1 3 377 389 2-s2.0-0034158310
3. Pijl H., Meinders A. E., Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Safety 1996 14 5 329 342 2-s2.0-0029967145
4. Nasrallah H., A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003 28 1 83 96 2-s2.0-0037214218 10.1016/S0306-4530(02)00114-2 (Pubitemid 36015663)
5. Fava M., Weight gain and antidepressants. Journal of Clinical Psychiatry 2000 61 11 37 41 2-s2.0-0033853466 (Pubitemid 30616693)
6. Carman C. L., Leung N. M., Gnberman A. H., Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Canadian Journal of Neurological Sciences 1997 24 3 240 244 (Pubitemid 27400384)
7. Cantu T. G., Korek J. S., Monoamine oxidase inhibitors and weight gain. Drug Intelligence and Clinical Pharmacy 1988 22 10 755 759 2-s2.0-0023791156
8. Weisler R. H., Johnston J. A., Lineberry C. G., Samara B., Branconnier R. J., Billow A. A., Comparison of bupropion and trazodone for the treatment of major depression. Journal of Clinical Psychopharmacology 1994 14 3 170 179 2-s2.0-0028240464 (Pubitemid 24182183)
9. Roy Chengappa K. N., Levine J., Rathore D., Parepally H., Atzert R., Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. European Psychiatry 2001 16 3 186 190 2-s2.0-0035040961 10.1016/S0924-9338(01)00562-4 (Pubitemid 32405590)
10. Wetterling T., Bodyweight gain with atypical antipsychotics: a comparative review. Drug Safety 2001 24 1 59 73 2-s2.0-0035153224 (Pubitemid 32113367)
11. McIntyre R. S., Cohen M., Zhao J., Alphs L., Macek T. A., Panagides J., Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders 2010 122 1-2 27 38 2-s2.0-77649340254 10.1016/j.jad.2009.12.028
12. Bishara D., Taylor D., Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatric Disease and Treatment 2009 5 1 483 490 2-s2.0-70449702359
13. McIntyre R. S., Cohen M., Zhao J., Alphs L., Macek T. A., Panagides J., Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disorders 2009 11 8 815 826 2-s2.0-71049147614 10.1111/j.1399-5618.2009. 00749.x
14. Weiden P. J., Cutler A. J., Polymeropoulos M. H., Wolfgang C. D., Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. Journal of Clinical Psychopharmacology 2008 28 7 S12 S19 2-s2.0-40849102838 10.1097/JCP.0b013e3181694f5a (Pubitemid 351397672)
15. Spina E., Cavallaro R., The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion on Drug Safety 2007 6 6 651 662 2-s2.0-38449090708 10.1517/14740338.6.6.651 (Pubitemid 351308277)
16. Meltzer H. Y., Bobo W. V., Nuamah I. F., Lane R., Hough D., Kramer M., Eerdekens M., Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Journal of Clinical Psychiatry 2008 69 5 817 829 2-s2.0-45249095185 (Pubitemid 351838691)
17. Cohen S., Glazewski R., Khan S., Khan A., Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Journal of Clinical Psychiatry 2001 62 2 114 116 2-s2.0-0035102066 (Pubitemid 32199868)
18. Russell J. M., Mackell J. A., Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001 15 7 537 551 2-s2.0-0034910756 (Pubitemid 32735379)
19. Ganguli R., Brar J. S., Ayrton Z., Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 2001 49 3 261 267 2-s2.0-0035971518 10.1016/S0920- 9964(00)00080-3 (Pubitemid 32453227)
20. Barak Y., No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. Journal of Clinical Psychiatry 2002 63 2 117 119 2-s2.0-0036181040 (Pubitemid 34173847)
21. Taylor D. M., McAskill R., Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 2000 101 6 416 432 2-s2.0-0034121256 10.1034/j.1600-0447.2000.101006416.x (Pubitemid 30365564)
22. Vanina Y., Podolskaya A., Sedky K., Shahab H., Siddiqui A., Munshi F., Lippmann S., Body weight changes associated with psycopharmacology. Psychiatric Services 2002 53 7 842 847 2-s2.0-0036303583 10.1176/appi.ps.53.7.842 (Pubitemid 34742766)
23. Kingsbury S. J., Fayek M., Trufasiu D., Zada J., Simpson G. M., The apparent effects of ziprasidone on plasma lipids and glucose. Journal of Clinical Psychiatry 2001 62 5 347 349 (Pubitemid 32545556)
24. Keck P. E., Versiani M., Potkin S., West S. A., Giller E., Ice K., Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry 2003 160 4 741 748 2-s2.0-0037512369 10.1176/appi.ajp.160.4.741 (Pubitemid 41079608)
25. Cohen S., Fitzgerald B., Okos A., Khan S., Khan A., Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry 2003 64 1 60 62 2-s2.0-0037266267 (Pubitemid 36182231)
26. Arato M., O'Connor R., Meltzer H. Y., A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology 2002 17 5 207 215 2-s2.0-0036739725
27. Frazier J. A., Biederman J., Tohen M., Feldman P. D., Jacobs T. G., Toma V., Rater M. A., Tarazi R. A., Kim G. S., Garfield S. B., Sohma M., Gonzalez-Heydrich J., Risser R. C., Nowlin Z. M., A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. Journal of Child and Adolescent Psychopharmacology 2001 11 3 239 250 (Pubitemid 32937636)
28. Littrell K. H., Petty R. G., Hilligoss N. M., Peabody C. D., Johnson C. G., Weight loss associated with olanzapine treatment. Journal of Clinical Psychopharmacology 2002 22 4 436 437 2-s2.0-0036321584 10.1097/00004714- 200208000-00018 (Pubitemid 34810337)
29. Søholm B., Lublin H., Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatrica Scandinavica 2003 107 5 344 350 2-s2.0-0037799123 10.1034/j.1600-0447.2003.00063.x (Pubitemid 36606151)
30. Lieberman J. A., Tollefson G., Tohen M., Green A. I., Gur R. E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R. M., Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003 160 8 1396 1404 2-s2.0-0042882529 10.1176/appi.ajp.160.8.1396 (Pubitemid 41070913)
31. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., Phillip M., Apter A., Weizman R., Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry 2002 41 3 337 343 2-s2.0-0036514352 10.1097/00004583-200203000-00014 (Pubitemid 38338156)
32. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., Poraz I., Frishman S., Constantini N., Zalsman G., Weizman A., Apter A., Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 2002 159 6 1055 1057 2-s2.0-0036276522 10.1176/appi.ajp.159.6.1055 (Pubitemid 34586957)
33. Shaw J. A., Lewis J. E., Pascal S., Sharma R. K., Rodriguez R. A., Guillen R., Pupo-Guillen M., A study of quetiapine: efficacy and tolerability in psychotic adolescents. Journal of Child and Adolescent Psychopharmacology 2001 11 4 415 424 2-s2.0-0035706262 (Pubitemid 34117291)
34. Brecher M., Rak I. W., Melvin K., Jones A. M., The long-term effect of quetiapine (Seroquel ™) monotherapy on weight in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice 2000 4 4 287 291 2-s2.0-0034534492 10.1080/13651500050517849 (Pubitemid 32057651)
35. Briffa D., Meehan T., Weight changes during clozapine treatment. Australian and New Zealand Journal of Psychiatry 1998 32 5 718 721 2-s2.0-0031736947 (Pubitemid 28497674)
36. Hong C. J., Lin C. H., Yu Younger W. Y., Yang K. H., Tsai S. J., Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001 11 3 265 268 2-s2.0-0035052252 10.1097/00008571-200104000- 00010 (Pubitemid 32319876)
37. Masi G., Mucci M., Millepiedi S., Clozapine in adolescent inpatients with acute mania. Journal of Child and Adolescent Psychopharmacology 2002 12 2 93 99 2-s2.0-0035986257 (Pubitemid 34779023)
38. Allison D. B., Mentore J. L., Heo M., Chandler L. P., Cappelleri J. C., Infante M. C., Weiden P. J., Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999 156 11 1686 1696 2-s2.0-0032751075 (Pubitemid 29517559)
39. Lamberti J. S., Bellnier T., Schwarzkopf S. B., Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry 1992 149 5 689 690 2-s2.0-0026509810
40. Potkin S. G., Saha A. R., Kujawa M. J., Carson W. H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S. R., Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003 60 7 681 690 2-s2.0-0038488945 10.1001/archpsyc.60.7.681 (Pubitemid 36818630)
41. Kaplan H. I., Sadock B. J., Synopsis of Psychiatry 1998 8th Baltimore, Md, USA Williams & Wilkins
42. Frank E., Kupfer D. J., Bulik C. M., Levenson J. A., Imipramine and weight gain during the treatment of recurrent depression. Journal of Affective Disorders 1990 20 3 165 172 2-s2.0-0025002216 10.1016/0165-0327(90)90140-4 (Pubitemid 20350928)
43. Prince J. B., Wilens T. E., Biederman J., Spencer T. J., Millstein R., Polisner D. A., Bostic J. Q., A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2000 10 3 193 204 2-s2.0-0033779916
44. Paradis C. F., Stack J. A., George C. J., Miller M. D., Pollock B. G., Rifai A. H., Mazumdar S., Perel J. M., Reynolds C. F., Nortriptyline and weight change in depressed patients over 60. Journal of Clinical Psychopharmacology 1992 12 4 246 250 2-s2.0-0026691050
45. Trivedi M., Rush A., A review of randomized controlled medication trials in major depression. Biological Psychiatry 1992 31 188 189
46. Chouinard G., Bupropion and amitriptyline in the treatment of depressed patients. Journal of Clinical Psychiatry 1983 44 5 121 129 2-s2.0-0020535059 (Pubitemid 13088850)
47. Anderson J. W., Greenway F. L., Fujioka K., Gadde K. M., McKenney J., O'Neil P. M., Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Research 2002 10 7 633 641 2-s2.0-0036636368 (Pubitemid 135688262)
48. Leinonen E., Skarstein J., Behnke K., Ågren H., Helsdingen J. Th., Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. International Clinical Psychopharmacology 1999 14 6 329 337 10.1097/00004850-199911000-00002 (Pubitemid 29531381)
49. Michelson D., Amsterdam J. D., Quitkin F. M., Reimherr F. W., Rosenbaum J. F., Zajecka J., Sundell K. L., Kim Y., Beasley C. M., Changes in weight during a 1-year trial of fluoxetine. American Journal of Psychiatry 1999 156 8 1170 1176 2-s2.0-0032818164 (Pubitemid 29374875)
50. Bouwer C. D., Harvey B. H., Phasic craving for carbohydrate observed with citalopram. International Clinical Psychopharmacology 1996 11 4 273 278 2-s2.0-0030452295 (Pubitemid 27049292)
51. Abell C. A., Farquhar D. L., Galloway S. M., Steven F., Philip A. E., Munro J. F., Placebo controlled double-blind trial of fluvoxamine maleate in the obese. Journal of Psychosomatic Research 1986 30 2 143 146 (Pubitemid 16119444)
52. Moon C. A. L., Jesinger D. K., The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. British Journal of Clinical Practice 1991 45 4 259 262
53. Tohen M., Baker R. W., Altshuler L. L., Zarate C. A., Suppes T., Ketter T. A., Milton D. R., Risser R., Gilmore J. A., Breier A., Tollefson G. A., Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry 2002 159 6 1011 1017 2-s2.0-0036274760 10.1176/appi.ajp.159.6.1011 (Pubitemid 34586948)
54. Harvey B. H., Bouwer C. D., Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clinical Neuropharmacology 2000 23 2 90 97 2-s2.0-0034002682 10.1097/00002826-200003000-00006 (Pubitemid 30212219)
55. Ribeiro L., Busnello J. V., Kauer-Sant'Anna M., Madruga M., Quevedo J., Busnello E. A. D., Kapczinski F., Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian Journal of Medical and Biological Research 2001 34 10 1303 1307 2-s2.0-0034748048 (Pubitemid 33014498)
56. Benkert O., Szegedi A., Kohnen R., Mirtazapine compared with paroxetine in major depression. Journal of Clinical Psychiatry 2000 61 9 656 663 2-s2.0-0033799094
57. Stip E., Tourjman V., Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clinical Therapeutics 2010 32 1 S3 S20 2-s2.0-75349098410 10.1016/j.clinthera.2010.01.021
58. Pigott T. A., Prakash A., Arnold L. M., Aaronson S. T., Mallinckrodt C. H., Wohlreich M. M., Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Current Medical Research and Opinion 2007 23 6 1303 1318 2-s2.0-34347242063 10.1185/ 030079907X188107 (Pubitemid 46998440)
59. Chengappa K. N. R., Chalasani L., Brar J. S., Parepally H., Houck P., Levine J., Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clinical Therapeutics 2002 24 10 1576 1584 2-s2.0-0036811240 10.1016/S0149-2918(02)80061-3 (Pubitemid 35351843)
60. Biton V., Mirza W., Montouris G., Vuong A., Hammer A. E., Barrett P. S., Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001 56 2 172 177 2-s2.0-0035936604 (Pubitemid 32095356)
61. Ginsberg, Proceedings of the 156th Annual Meeting of the American Psychiatric Association May 2003 San Francisco, Calif, USA
62. Lampl Y., Eshel Y., Rapaport A., Sarova-Pinhas I., Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clinical Neuropharmacology 1991 14 3 251 255 2-s2.0-0025740492
63. Luef G., Abraham I., Haslinger M., Trinka E., Seppi K., Unterberger I., Alge A., Windisch J., Lechleitner M., Bauer G., Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. Journal of Neurology 2002 249 7 835 841 2-s2.0-18444383349 10.1007/s00415-002-0731-3 (Pubitemid 34754219)
64. Baptista T., Teneud L., Contreras Q., Alastre T., Burguera J. L., De Burguera M., De Baptista E., Weiss S., Hernandez L., Lithium and body weight gain. Pharmacopsychiatry 1995 28 2 35 44 2-s2.0-0028918641
65. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., Poraz I., Frishman S., Constantini N., Zalsman G., Weizman A., Apter A., Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 2002 159 6 1055 1057 2-s2.0-0036276522 10.1176/appi.ajp.159.6.1055 (Pubitemid 34586957)
66. Allison D. B., Casey D. E., Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001 62 7 22 31 2-s2.0-0035041926 (Pubitemid 32402182)
67. Kobayashi T., Ikeda K., Kumanishi T., Effects of clozapine on the δ-and -opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes. British Journal of Pharmacology 1998 123 3 421 426 2-s2.0-0031985627 10.1038/sj.bjp.0701621 (Pubitemid 28059710)
68. Curzon G., Gibson E. L., Oluyomi A. O., Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends in Pharmacological Sciences 1997 18 1 21 25 2-s2.0-0031015701 10.1016/S0165- 6147(96)01003-6 (Pubitemid 27072875)
69. Strosberg A. D., Pietri-Rouxel F., Function and regulation of the β 3-adrenoceptor. Trends in Pharmacological Sciences 1996 17 10 373 381 2-s2.0-0030273411
70. Goodwin G. M., How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Journal of Clinical Psychiatry 1996 57 4 9 13 2-s2.0-0030011182 (Pubitemid 26177338)
71. Stahl S. H., Essential Psychopharmacology 1996 New York, NY, USA Cambridge University Press
72. Clark N. G., Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 27 2 596 601 2-s2.0-0842348094 10.2337/diacare.27.2.596 (Pubitemid 38180442)
73. Weiss D., How to help your patients lose weight: current therapy for obesity. Cleveland Clinic Journal of Medicine 2000 67 10 739 754 2-s2.0-0033779711
74. Thomas P. R., Weighing the Options: Criteria for Evaluating Weight Management Programs 1995 Washington, DC, USA National Academy Press
75. Hannum S. M., Carson L., Evans E. M., Canene K. A., Petr E. L., Bui L., Erdman J. W., Use of portion-controlled entrees enhances weight loss in women. Obesity Research 2004 12 3 538 546 2-s2.0-3042531635 (Pubitemid 41132534)
76. Umbricht D., Flury H., Bridler R., Cognitive behavior therapy for weight gain. American Journal of Psychiatry 2001 158 6 971 972 2-s2.0-0034974090 10.1176/appi.ajp.158.6.971
77. Connolly H. M., Crary J. L., McGoon M. D., Hensrud D. D., Edwards B. S., Edwards W. D., Schaff H. V., Valvular heart disease associated with fenfluramine phentermine. New England Journal of Medicine 1997 337 9 581 588 2-s2.0-0030876952 10.1056/NEJM199708283370901 (Pubitemid 27360757)
78. Kelly K. P., Kirschenbaum D. S., Immersion treatment of childhood and adolescent obesity: the first review of a promising intervention. Obesity Reviews 2011 12 1 37 49
79. Werrij M. Q., Jansen A., Mulkens S., Elgersma H. J., Ament A. J. H. A., Hospers H. J., Adding cognitive therapy to dietetic treatment is associated with less relapse in obesity. Journal of Psychosomatic Research 2009 67 4 315 324 2-s2.0-70249135248 10.1016/j.jpsychores.2008.12.011
80. Saper R. B., Eisenberg D. M., Phillips R. S., Common dietary supplements for weight loss. American Family Physician 2004 70 9 1731 1738 2-s2.0-7744226273 (Pubitemid 39463386)
81. Pittler M. H., Ernst E., Dietary supplements for body-weight reduction: a systematic review. American Journal of Clinical Nutrition 2004 79 4 529 536 2-s2.0-2142655783 (Pubitemid 41103893)
82. Davidson J. R. T., Abraham K., Connor K. M., McLeod M. N., Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biological Psychiatry 2003 53 3 261 264 2-s2.0-0037304640 10.1016/S0006-3223(02)01500-7 (Pubitemid 36135938)
83. Docherty J. P., Sack D. A., Roffman M., Finch M., Komorowski J. R., A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. Journal of Psychiatric Practice 2005 11 5 302 314 2-s2.0-27544510736 10.1097/00131746-200509000-00004 (Pubitemid 41540225)
84. Bray G. A., Use and abuse of appetite-suppressant drugs in the treatment of obesity. Annals of Internal Medicine 1993 119 7 707 713 2-s2.0-0027363269 (Pubitemid 23313694)
85. Klonoff D. C., Greenway F., Drugs in the pipeline for the obesity market. Journal of Diabetes Science and Technology 2008 2 5 913 918
86. Halford J. C. G., Boyland E. J., Blundell J. E., Kirkham T. C., Harrold J. A., Pharmacological management of appetite expression in obesity. Nature Reviews Endocrinology 2010 6 5 255 269 2-s2.0-77951665710 10.1038/nrendo.2010.19
87. Kaplan L. M., Pharmacologic therapies for obesity. Gastroenterology Clinics of North America 2010 39 1 69 79 2-s2.0-77349115193 10.1016/j.gtc.2010. 01.001
88. Aronne L. J., Halseth A. E., Burns C. M., Miller S., Shen L. Z., lshen@amylin.com Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity 2010 18 9 1739 1746 10.1038/oby.2009.478
89. Bray G. A., Ryan D. H., Gordon D., Heidingsfelder S., Cerise F., Wilson K., A double-blind randomized placebo-controlled trial of sibutramine. Obesity Research 1996 4 3 263 270 2-s2.0-0030147221 (Pubitemid 126690229)
90. Lean M. E. J., Sibutramine-a review of clinical efficacy. International Journal of Obesity 1997 21 1 S30 S36 2-s2.0-0030993522 (Pubitemid 27160697)
91. Weintraub M., Rubio A., Golik A., Byrne L., Scheinbaum M. L., Sibutramine in weight control: a dose-ranging, efficacy study. Clinical Pharmacology and Therapeutics 1991 50 3 330 337 2-s2.0-0025938842
92. Stock M. J., Sibutramine: a review of the pharmacology of a novel anti-obesity agent. International Journal of Obesity 1997 21 supplement 1 S25 S29 (Pubitemid 27160696)
93. Guerciolini R., Mode of action of orlistat. International Journal of Obesity 1997 21 supplement 3 S12 S23 (Pubitemid 27271984)
94. van Gaal L. F., Broom J. I., Enzi G., Toplak H., Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. European Journal of Clinical Pharmacology 1998 54 2 125 132 2-s2.0-0031946729 10.1007/s002280050433 (Pubitemid 28204265)
95. Sjöström L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H. P. F., Krempf M., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998 352 9123 167 172 2-s2.0-0032543870 10.1016/S0140-6736(97)11509-4 (Pubitemid 28327800)
96. McNeely W., Benfield P., Drent L., Pi-Sunyer F. X., Orlistat. Drugs 1998 56 2 241 250 2-s2.0-0031849958 (Pubitemid 28392271)
97. Hollander P. A., Elbein S. C., Hirsch I. B., Kelley D., McGill J., Taylor T., Weiss S. R., Crockett S. E., Kaplan R. A., Comstock J., Lucas C. P., Lodewick P. A., Canovatchel W., Chung J., Hauptman J., Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 21 8 1288 1294 2-s2.0-0031904104 10.2337/diacare.21.8.1288 (Pubitemid 28365685)
98. Zhi J., Melia A. T., Koss-Twardy S. G., Arora S., Patel I. H., The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β -carotene in healthy volunteers. Journal of Clinical Pharmacology 1996 36 2 152 159 2-s2.0-0029989469 (Pubitemid 26082401)
99. Melia A. T., Koss-Twardy S. G., Zhi J., The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. Journal of Clinical Pharmacology 1996 36 7 647 653 2-s2.0-0029784311 (Pubitemid 26260546)
100. Schwartz T. L., Beale M., Psychotropic induced weight gain alleviated with orlistat. Psychopharm Bulletin 2003 37 1 5 8
101. Floris M., Lejeune J., Deberdt W., Effect of amantadine on weight gain during olanzapine treatment. European Neuropsychopharmacology 2001 11 2 181 182 2-s2.0-0035063715 10.1016/S0924-977X(01)00072-4 (Pubitemid 32335561)
102. Breier A., Tanaka Y., Roychowdhury S., Nizatidine for the prevention of weight gain during olanzapine treatment in schizophrenia and related disorders: a randomised controlled double-blind study. Proceedings of the Meeting of the Colleges of Psychiatric and Neurologic Pharmacists March 2001 San Antonio, Tex, USA
103. Lessig M. C., Shapira N. A., Murphy T. K., Topiramate for reversing atypical antipsychotic weight gain. Journal of the American Academy of Child and Adolescent Psychiatry 2001 40 12, article 1364 2-s2.0-0035726673
104. Ghaemi S. N., Manwani S. G., Katzow J. J., Ko J. Y., Goodwin F. K., Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Annals of Clinical Psychiatry 2001 13 4 185 189 2-s2.0-0035727161 10.1023/A:1014627001201 (Pubitemid 34273558)
105. Vieta E., Torrent C., Garcia-Ribas G., Gilabert A., Garcia-Parés G., Rodriguez A., Cadevall J., García-Castrillón J., Lusilla P., Arrufat F., Use of topiramate in treatment-resistant bipolar spectrum disorders. Journal of Clinical Psychopharmacology 2002 22 4 431 435 2-s2.0-0036329889 10.1097/00004714-200208000-00017 (Pubitemid 34810336)
106. Ellinger L. K., Ipema H. J., Stachnik J. M., Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic- induced weight gain. Annals of Pharmacotherapy 2010 44 4 668 679 2-s2.0-77950612221 10.1345/aph.1M550
107. Morrison J. A., Cottingham E. M., Barton B. A., Metformin for weight loss in pediatric patients taking psychotropic drugs. American Journal of Psychiatry 2002 159 4 655 657 2-s2.0-0036221125 10.1176/appi.ajp.159.4.655 (Pubitemid 34274950)
108. Klein D. J., Cottingham E. M., Sorter M., Barton B. A., Morrison J. A., A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry 2006 163 12 2072 2079 2-s2.0-33846294762 10.1176/appi.ajp.163.12.2072 (Pubitemid 46114226)
109. Nasrallah H. A., Meyer J. M., Goff D. C., McEvoy J. P., Davis S. M., Stroup T. S., Lieberman J. A., Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 2006 86 1-3 15 22 2-s2.0-33747180826 10.1016/j.schres.2006.06.026 (Pubitemid 44234064)